UBS says this sector remains a high-quality, defensive investment theme

UBS reiterates its positive stance on the medical devices sector, viewing it as a high-quality, defensive investment theme driven by long-term demographic shifts, rising global demand, and continuous product innovation. The bank projects a $159 billion market with mid-single-digit annual growth, highlighting strong segments like diabetes technology, and anticipates sustained valuations despite regional challenges in China and limited downside from new obesity drugs.

Analysis

UBS has reiterated its positive outlook on the medical devices sector, positioning it as a defensive investment theme with durable, long-term growth drivers. The bank projects a $159 billion target market expanding at a mid-single-digit annual rate, underpinned by structural tailwinds such as global aging, rising life expectancy, and increasing adoption in emerging markets. The global population over 65 is forecast to increase by nearly 20% by 2030, providing a powerful demographic impetus. Specific segments are exhibiting exceptional growth; diabetes technologies, including automated insulin delivery pumps and continuous glucose monitors, are expanding at over 15% annually. The analysis highlights that ongoing product innovation is critical for maintaining pricing power and shifting the product mix toward higher-margin offerings. While the post-pandemic surge in surgical procedures is normalizing, demand remains above pre-COVID levels. The sector's defensive nature is reinforced by stable demand in Europe and the potential for the Affordable Care Act to mitigate recessionary impacts in the U.S. However, performance is not uniform, with sales in China remaining subdued due to macroeconomic softness and pricing pressures from its value-based procurement system. UBS views the potential downside from new obesity drugs as limited, arguing that increased longevity will likely sustain or even grow overall device utilization in the long run.

Key Decisions for Investors

• Consider overweighting exposure to the medical devices sector for its defensive qualities and structural growth driven by non-cyclical demographic trends.
• Focus on companies leading in high-growth sub-sectors, particularly diabetes technology which is growing at over 15% annually, as well as innovators in orthopedics and cardiovascular devices with strong pricing power.
• Monitor regional exposures, specifically recognizing the ongoing weakness and pricing pressure in the Chinese market, which could weigh on companies with significant revenue concentration in that region.
• Maintain the view that new obesity drugs pose a limited threat to the sector's long-term thesis, as extended lifespans are expected to offset any reduction in specific procedures.